Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

With an average analyst rating of hold, Novartis is clearly not a favorite. But some of the best stock picks are contrarian ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF115.00. The company’s shares opened today at CHF96.53. Papadakis ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

The pharmaceutical company said Thursday the drug did not meet its primary endpoint of sustained remission after 52 weeks of use in a phase three trial. Novartis said it will complete a full ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...